Item 9 Labs Corp (INLB)
US Market

Item 9 Labs (INLB) Stock Price & Analysis


INLB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.04 - $1.50
Previous Close$0.11
Average Volume (3M)26.46K
Market Cap
Enterprise Value$43.24M
Total Cash (Recent Filing)$21.78K
Total Debt (Recent Filing)$32.59M
Price to Earnings (P/E)-0.3
May 17, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding100,787,770
10 Day Avg. Volume28,812
30 Day Avg. Volume26,459
Standard Deviation0.27
Financial Highlights & Ratios
Price to Book (P/B)-1.30
Price to Sales (P/S)0.53
Price to Cash Flow (P/CF)11817.20
P/FCF Ratio-1.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.10
Enterprise Value/Gross Profit5.91
Enterprise Value/Ebitda-1.96
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Item 9 Labs Corp’s price range in the past 12 months?
Item 9 Labs Corp lowest stock price was $0.04 and its highest was $1.50 in the past 12 months.
    What is Item 9 Labs Corp’s market cap?
    Currently, no data Available
    When is Item 9 Labs Corp’s upcoming earnings report date?
    Item 9 Labs Corp’s upcoming earnings report date is May 17, 2023 which is in 48 days.
      How were Item 9 Labs Corp’s earnings last quarter?
      Item 9 Labs Corp released its earnings results on Feb 14, 2023. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.05 by $0.02.
        Is Item 9 Labs Corp overvalued?
        According to Wall Street analysts Item 9 Labs Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Item 9 Labs Corp pay dividends?
          Item 9 Labs Corp does not currently pay dividends.
          What is Item 9 Labs Corp’s EPS estimate?
          Item 9 Labs Corp’s EPS estimate is -$0.04.
            How many shares outstanding does Item 9 Labs Corp have?
            Item 9 Labs Corp has 100,787,770 shares outstanding.
              What happened to Item 9 Labs Corp’s price movement after its last earnings report?
              Item 9 Labs Corp reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.05. Following the earnings report the stock price went up 25%.
                Which hedge fund is a major shareholder of Item 9 Labs Corp?
                Currently, no hedge funds are holding shares in INLB


                Item 9 Labs Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Item 9 Labs Corp

                Item 9 Labs Corp. engages in the development, manufacture, and distribution of nasal breathing devices. Its products includes filtered, and non-filtered nasal dilator-breathing devices. The filtered product also contains 3M filtration media for allergy sufferers. The company was founded by Bryce Skalla on June 15, 2010 and is headquartered in Scottsdale, AZ.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Elite Pharmaceuticals
                Cumberland Pharmaceuticals
                Akari Therapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis